This study is currently not recruiting participants.

A Phase 2a Multi-Center Study of 18F-FDG PET Safety and Tolerability of AZD0530 in Mild Alzheimer's Disease

Study on Investigational Medication for Alzheimer's Disease

Not Recruiting
55 years - 85 years
All
Phase N/A
1 Location

Brief description of study.

The purpose of this research study is to determine whether AZD0530 is safe and effective in slowing decline in brain metabolism, memory and daily function in people with Alzheimer?s disease (AD).

Detailed description of study

The purpose of this study is to test whether an oral experimental drug, AZD0530, will slow progression in mild-stage Alzheimer's disease.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Alzheimer's disease
  • Age: 55 years - 85 years
  • Gender: All

This study investigates whether an investigational medication is safe and effective in slowing the decline in brain metabolism, memory, and daily function in people with Alzheimer's disease. Alzheimer's disease is a condition that affects the brain, leading to problems with memory and thinking skills.

Participants will take an oral investigational medication to see if it can slow the progression of mild-stage Alzheimer's disease. The study will involve monitoring the effects of the medication on brain function and daily activities.

  • Who can participate: Participants aged 50-85 with a diagnosis of mild-stage Alzheimer's disease may be eligible. Key factors include stable health condition and no participation in other clinical trials.
  • Study details: Participants will take an oral investigational medication to assess its impact on Alzheimer's disease progression. A placebo may be used for comparison.
Updated on 19 Feb 2024. Study ID: 1501331796

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team